Several years ago our scientists (led by Professor David Allsop) at Lancaster University developed a drug that blocks the formation of the 'senile plaques' that are found in the brains of victims of Alzheimer's disease/dementia. Our drug blocks these plaques from forming, along with their toxic effect on brain cells. It is highly stable in the body and we know that it also preserves memory.A North West based Clinical Research organisation (MAC plc) have agreed to progress our treatment towards  human clinical trials, and although this is good news indeed, there are still a lot of experiments that need completing. 

And so, we need to raise funds to ensure that this laboratory work is carried out, and our drug quickly gets to the point where it can be given to people who are experiencing the first symptoms of Alzheimer’s disease. It is estimated that about 850,000 people in the UK suffer from dementia today, and that number is only going to increase as the population gets older.